Polyphenolics President Anil Shrikhande sat down with Nutraceuticals World reporter Sheldon Baker to discuss the significance of the clinical trials conducted at U.C. Davis using MegaNatural®-BP. Shrikhande, a 30-year research and development veteran, and an inventor who holds eight patents, is the driving force behind the development of the brand.
“The importance of this original research, conducted by world leaders in this area, is that it allows us to differentiate our grape seed extract from other commodity brands because ours is potentially the only grape seed extract that has the unique ability to reduce blood pressure,” says Shrikhande.
He further explains the company’s commitment to sustainability: “As a division of Constellation Brands, Polyphenolics has access to an abundant supply of quality U.S.-grown grapes. We maintain total control over the entire manufacturing process, from raw material procurement to final extraction. This synergistic business model also results in all parts of the grape being utilized: the juice is used to make wine, the unfermented grape seeds are used to manufacture MegaNatural®-BP, and the grape skin and pulp provide the raw materials for producing our grape pomace extract.”
In the accompanying article on Nutraceuticals World’s website, Shrikhande also candidly discusses his company’s commitment to its customers. “As a president I am always ready to communicate with customers usually by providing key information that they can use for their competitive advantage. Customer satisfaction in all aspects of our business. At Polyphenolics we provide exceptional technical support, meet shipping deadlines and consistently provide product and service quality.” Polyphenolics just received its fourth patent for MegaNatural®-BP, a brand of grape seed extract shown in clinical studies to help lower blood pressure in hypertensive individuals. MegaNatural- BP is unique in its structure and composition, and has greater bioavailability and absorption compared to other grape seed extracts.